RT Journal Article
SR Electronic
T1 Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.21.20109397
DO 10.1101/2020.05.21.20109397
A1 Varshneya, Meera
A1 Irurzun-Arana, Itziar
A1 Campana, Chiara
A1 Dariolli, Rafael
A1 Gutierrez, Amy
A1 Pullinger, Taylor K.
A1 Sobie, Eric A.
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.21.20109397.abstract
AB Many drugs that have been proposed for treatment of COVID-19 are reported to cause cardiac adverse events, including ventricular arrhythmias. In order to properly weigh risks against potential benefits, particularly when decisions must be made quickly, mathematical modeling of both drug disposition and drug action can be useful for predicting patient response and making informed decisions. Here we explored the potential effects on cardiac electrophysiology of 4 drugs proposed to treat COVID-19: lopinavir, ritonavir, chloroquine, and azithromycin, as well as combination therapy involving these drugs. Our study combined simulations of pharmacokinetics (PK) with quantitative systems pharmacology (QSP) modeling of ventricular myocytes to predict potential cardiac adverse events caused by these treatments. Simulation results predicted that drug combinations can lead to greater cellular action potential prolongation, analogous to QT prolongation, compared with drugs given in isolation. The combination effect can result from both pharmacokinetic and pharmacodynamic drug interactions. Importantly, simulations of different patient groups predicted that females with pre-existing heart disease are especially susceptible to drug-induced arrhythmias, compared males with disease or healthy individuals of either sex. Overall, the results illustrate how PK and QSP modeling may be combined to more precisely predict cardiac risks of COVID-19 therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch in Dr. Sobie's laboratory is supported by the National Institutes of Health (U01 HL136297, U54 HG008098), the National Science Foundation (MCB 1615677) and the US Food and Drug Administration (75F40119C10021). Meera Varshneya is supported by a fellowship from the National Heart Lung and Blood institute (F31 HL149358) and has previously been supported by a training grant from the National Institute of General Medical Sciences (T32 GM062754).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A